Autres langues Collegium Pharmaceutical, Inc.

Actions

COLL

US19459J1043

Produits pharmaceutiques

Temps réel estimé Cboe BZX 18:23:48 12/10/2026			Varia. 5j.	Varia. 1 janv.
21,92 ^USD	-0,75 %		+0,39 %	-52,58 %

09/10	Les perspectives de Collegium Pharmaceutical soutenues par les tendances du TDAH et le faible risque lié aux médicaments génériques, selon Oppenheimer	MT
06/10	Collegium Pharmaceutical, Inc. lance « Start Talking ADHD », un programme d’accompagnement pratique pour aider les familles à gérer les soins, l’école et le quotidien	CI

Autres langues

09/10	Collegium Pharmaceutical Outlook Supported by ADHD Trends, Low Generic Drug Risk, Oppenheimer Says
06/10	Collegium Pharmaceutical, Inc. Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life
06/10	Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life
23/09	Collegium's Durable Cash Flow From Pain Portfolio Poised to Support Further Business Development, Oppenheimer Says
08/09	Collegium to Participate in Upcoming Investor Conferences
13/08	Collegium Pharmaceutical Enters $50 Million Accelerated Share Repurchase Agreement
13/08	Collegium Announces $50 Million Accelerated Share Repurchase Program
06/08	Collegium Pharmaceutical, Inc. Revises Earnings Guidance for the Year 2026
06/08	Collegium Pharmaceutical, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	(COLL) Collegium Pharmaceutical Expects 2026 Net Product Revenue Range $825M to $855M
06/08	Earnings Flash (COLL) Collegium Pharmaceutical, Inc. Reports Q2 Revenue $199.9M, vs. FactSet Est of $199.6M
06/08	Earnings Flash (COLL) Collegium Pharmaceutical, Inc. Posts Q2 Adjusted EPS $1.92 per Share, vs. FactSet Est of $1.72
06/08	Collegium Pharmaceutical: Q2 Earnings Snapshot
06/08	Tranche Update on Collegium Pharmaceutical, Inc.'s Equity Buyback Plan announced on July 7, 2025.
06/08	Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress
06/08	Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress
23/07	Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026
23/07	Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026
20/07	Collegium Pharmaceutical to Relocate HQ to One Lincoln in Boston
20/07	Collegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in Boston
05/06	Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
27/05	Collegium to Participate in 2026 Jefferies Global Healthcare Conference
15/05	Collegium Pharmaceutical, Inc. Announces Appointment of Michael Donovan as Director
12/05	Collegium completes acquisition of Azstarys® from Corium Therapeutics
12/05	Collegium Pharmaceutical Completes Azstarys Acquisition, Raises 2026 Net Product Revenue Guidance